FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.

Ekterly becomes the first FDA-approved oral on-demand treatment for hereditary angioedema in patients aged 12 years and older ...

H2 2025 catalysts to watch, biopharma implications of President Trump’s tax law, KalVista’s new hereditary angioedema drug that Marty Makary reportedly tried to reject, another lawsuit aimed at Health ...

Health groups led by the American Academy of Pediatrics filed a lawsuit against HHS Secretary Robert F. Kennedy Jr. on Monday ...

KalVista Pharmaceuticals showed 0% EPS growth last quarter, while sales growth came in at 0%. Keep an eye out for the company's next round of numbers on or around Jul. 8. KalVista ...

The Food and Drug Administration (FDA) has approved Ekterly ® (sebetralstat) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

The domestic equity benchmarks ended with modest gains today, buoyed by positive sentiment after U.S. President Donald Trump postponed the implementation of new tariffs to August 1. The Nifty settled ...

S&P Global Ratings is considering whether to reclassify Centene Corp.'s credit ratings to junk, which would strongly impact its borrowing power. Centene, the top seller of ACA health plans, is ...

The United States market remained flat over the last week, but it has risen 13% over the past 12 months with earnings forecasted to grow by 15% annually. In this context, identifying high growth tech ...

A Senate committee will vote this week on whether to advance the nomination of Susan Monarez, President Donald Trump’s pick ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...